[Company Profile] Pico-Tesla Magnetic Therapies

Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease. The randomized, double-blind, placebo-controlled study will explore whether the magnetic fields generated by Pico-Tesla’s patented Resonator™ system are effective as an adjunctive therapy to oral medication in reducing hemoglobin A1c levels. Hemoglobin A1c levels are used as a measure of blood sugar control. The higher a patient’s levels of hemoglobin A1c, the higher the patient’s risk of developing complications from diabetes.

The theory behind Pico-Tesla’s Magnaceutical™ Therapy suggests that in a disease state, the electromagnetic fields of the affected atoms are disrupted. The Magnaceutical™ Therapy system consists of an extremely low-level electromagnetic field (EMF) applied by a device called the Resonator™. The Resonator™ sends energy into the body to nudge these atoms back into resonance, providing relief from symptoms related to conditions such as type 2 diabetes and Parkinson’s disease. The system is intended to be non-invasive and low-risk.  Patients in the pilot study will be treated with the Resonator device three times per week for 13 weeks, at about 90 minutes per treatment. The study will involve up to 165 patients. 

Out of the 18 million confirmed cases of diabetes in the U.S., over 90 percent have type 2 diabetes. The prevalence of type 2 diabetes more than doubled between 1990 and 2005—enough for the U.S. Centers of Disease Control to classify the disease as an epidemic.

The company has another study underway; it recently began a Phase III clinical trial of its Magnaceutical™ Therapy as an adjunctive treatment for the symptoms of Parkinson’s disease (PD). Parkinson’s is a chronic, degenerative disease affecting over 1.5 million people in the United States. The disease affects functions such as motor control and speech. Current medications to treat PD may have unpleasant side effects such as depression, low blood pressure, and hallucinations. Pilot data from 2008 suggested that motor symptoms of PD improved 20-53 percent compared to placebo, while non-motor symptoms improved by 17-46 percent after 8 weeks of treatment. Improvement of several symptoms lasted up to two months after treatment. The company plans to apply for 501(k) clearance with the U.S. Food and Drug Administration.

Related video: OneMedPlace corporate profile of Pico-Tesla.

The comments are closed.